Mid*Lands IRB
, LLC is pleased to announce that it has been awarded accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) at the September meeting of its Council on Accreditation.
Located in the Kansas City metro area, Mid*Lands is an independent review board (IRB) that protects the rights and welfare of research study participants. Mid*Lands IRB specializes in providing customized, personalized, and responsive services for its client partners. Mid*Lands provides IRB review for clients nationwide for all phases of research in all therapeutic areas. Mid*Lands has extensive experience in multi-site trials, with two Boards that meet weekly.
AAHRPP promotes high-quality research through an accreditation process that helps organizations worldwide strengthen their human research protection programs (HRPPs).
An independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven, educational model to ensure that HRPPs meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence through policies, procedures, and practices of their commitment to scientifically and ethically sound research and continuous improvement.
As the "gold seal," AAHRPP accreditation offers assurances to research participants, researchers, sponsors, government regulators, and the general public that an HRPP is focused first and foremost on excellence.
"After a tremendous amount of work by both our staff and our IRB Members, Mid*Lands has achieved full accreditation," according to Cathy Owen, CIM, CIP, CCRP, President and CEO of Mid*lands. "The rigorous and comprehensive accreditation mandated by AAHRPP provides Mid*Lands with the ability to achieve even higher levels of protection for human research participants," Ms. Owen said.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.